Compare Abeona Therapeutics Inc (ABEO) vs Krispy Kreme Inc (DNUT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Krispy Kreme Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Krispy Kreme Inc trades at $3.48 (market cap $572.37M). The key difference: Krispy Kreme Inc is the larger of the two by market cap, and Krispy Kreme Inc pays a 3.47% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | DNUT | |
|---|---|---|
Market Cap | $373.32M | $572.37M |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $4.70 |
52-Week Low | $4.17 | $2.92 |
Enterprise Value | $228.22M | $1.77B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Krispy Kreme (DNUT) trades at $3.32, down 5.41% today, with a bearish technical signal and neutral oscillators. The company reported Q1 2026 EPS of -$0.05, missing expectations, though Q4 2025 and Q3 2025 beat estimates. Revenue for 2025 was $1.52B with a net loss of -$515.77M, reflecting a -33.36% net margin. Analyst consensus is 50% buy, 35.71% hold, and 14.29% sell. Recent news highlights automation efforts and new product launches to attract younger consumers.
The outlook remains challenging with persistent losses and high debt, but strategic pivots to capital-light models and international growth offer potential. Risks include execution missteps and competitive pressures. Investors should weigh turnaround progress against financial instability, with Q2 2026 earnings on August 6, 2026, as a key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →
